Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells

Blood

Volumn 89, Issue 1, 1997, Pages 227-234

  Chauhan, Dharminder ^a   Kharbanda, Surender ^a   Ogata, Atsushi ^a   Urashima, Mitsuyoshi ^a   Teoh, Gerrard ^a   Robertson, Michael ^a   Kufe, Donald W ^a   Anderson, Kenneth C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FAS ANTIGEN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL PROTECTION; DNA CLEAVAGE; EARLY RESPONSE GENE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; ONCOGENE C JUN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRESS;

EID: 0031029911     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.1.227.227_227_234     Document Type: Article

References (67)

1. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoka H, Tang O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332:83, 1988
2. Klein B, Zhang X, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517, 1989
3. Lichtenstein A, Berenson J, Norman D, Chang M-P, Carlile A: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266, 1989
4. Anderson KC, Jones RC, Morimoto C, Leavitt P, Barut B: Response of purified myeloma cells to hematopoietic growth factors. Blood 73:1915, 1989
5. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC: Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688, 1991
6. Barut BA, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohrbacher A, Fingeroth J, Anderson KC: Role of interleukin-6 in the growth of myeloma derived cell lines. Leuk Res 16:951, 1992
7. Klein B, Zhang XG, Yang LZ, Bataille R: Interleukin-6 in human multiple myeloma. Blood 85:863, 1995
8. Ogata A, Chauhan D, Urashima M, Teoh G, Hatziyanni M, Vidriales MB, Schlossman RL, Anderson KC: Interleukin-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activatied protein kinase cascade. (submitted)
9. Urashima M, Ogata A, Chauhan D, Vidriales MB, Teoh G Hoshi Y, Schlossman RL, DeCaprio JA, Anderson KC: Interleukin-6 promotes multiple myeloma cell growth via phophorylation of Retinoblastoma protein. Blood (in press)
10. 16INK4A) protein expression is associated with interleukin-6 mediated multiple myeloma cell growth. 88:2219, 1996
11. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248, 1995
12. Hardin J, Macleod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84:3063, 1994
13. Willie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68:251, 1980
14. Collins RJ, Verscher LA, Harmon BV, Prentice RL, Pope JH, Kerr JF: Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro. Br J Haematol 71:343, 1989
15. Raff MC: Social control on cell survival and cell death. Nature 356:397, 1992
16. Kouy MJ, Boudurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248:378, 1990
17. Williams GT, Smith CA, Spooner E, Dexter TM, Taylor DR: Haematopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature 343:76, 1990
18. Kerr JFR, Harmon BV: Definition and incidence of apoptosis: A historical perspective, in Tomeri LD, Cope FO (eds): Current Communications 3-Cell and Molecular Biology. Apoptosis: The Molecular basis of Cell Death. Cold Spring Harbor, NY, Cold Spring Laboratory, 1991, p 5
19. Cotter TG, Lennon SV, Glynn JG, Martin SJ: Cell death via apoptosis and its relationship to growth, development and differentiation of both tumor and normal cells. Anticancer Res 10:1153, 1990
20. Yonehara S, Ishi A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a surface antigen codownregulated with the receptor of tumor necrosis factor. J Exp Med 181:1747, 1989
21. Itoh N, Yonehara A, Ishi M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233, 1991
22. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas G, Li-Weber CM, Richards S, Dhein J, Trauth BC, Ponsting H, Krammer PH: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267:10709, 1992
23. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J: Functional consequences of APO-1/Fas(CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymph 17:51, 1995
24. Suda T, Takashi T, Goldstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169, 1993
25. Westerndorf JJ, Lammeret J, Jelinek DF: Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85:3566, 1995
26. Shima Y, Nishimoto N, Ogata A, Fuji Y, Yoshizaki K, Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD-95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85:757, 1995
27. Hata H, Hiromitsu M, Takeya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kawano F, Takatsuki K: Expression of Fas/APO-1 (CD 95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 86:1939, 1995
28. Schwarze MMK, Hawley RG: Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated upregulation of bcl-xl. Cancer Res 55:2262, 1995
29. Sherman M, Stone R, Datta R, Bernstein S, Kufe D: Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem 265:3320, 1990
30. Gunji H, Kharbanda S, Kufe D: Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res 51:741, 1991
31. Devary Y, Gottleib RA, Lau LF, Karin M: Rapid and preferential activation of the c-jun gene during the mammalian UV response. Mol Cell Biol 11:2804, 1991
32. Kyriakis JM, Benerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156, 1994
33. Derijard B, Hibi M, Wu IH, Barret T, Su B, Deng T, Karin M, Davis RJ: JNK1: A protein kinase stimulated by UV light and H-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025, 1994
34. Hibi M, Lin A, Smeal T, Minden A, Karin M: Identification of an oncoprotein and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135, 1993
35. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Wechselbaum RR, Kufe DW: Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376:785, 1995
36. Kharbanda S, Saleem A, Shafman T, Emoto Y, Taneja N, Rubin E, Weichselbaum R, Woodgett J, Avruch J, Kyriakis J, Kufe D: Ionizing radiation stimulates a Grb2-mediated association of the stress-activated protein kinase with phosphatidylinositol 3-kinase. J Biol Chem 270:18871, 1995
37. Roy C, Brown D, Little JE, Valentine BK, Walker PR, Sikorska M, Leblanc J, Caly N: The topoisomerase II inhibits teniposide (VM-26) induced apoptosis in unstimulated mature murine lymphocytes. Exp Cell Res 200:416, 1992
38. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326, 1995
39. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Friedman AH, Fuks Z, Kolesnick RN: Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75, 1996
40. Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P: A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 67:629, 1993
41. Frank R: A simple and rapid method for detection of apoptosis in human cells. Nucleic Acids Res 20:5243, 1992
42. Chauhan D, Kharbanda S, Uchiyama H, Urashima M, Sen J, Fuguso R, Kufe DW, Anderson KC: Identification of upstream signals regulating interleukin-6 gene expression during in vitro treatment of human B cells with pokeweed mitogen. Blood 84:2243, 1994
43. Angel P, Allegretto EA, Okino ST, Hattori K, Boyle WJ, Hunter T, Karin M: Oncogene jun encodes a sequence-specific transactivator similar to AP-1 Nature 332:166, 1988
44. Cleveland DW, Lopata MA, MacDonald RJ. Cowan NJ, Rutter WJ, Kirshner M: Number and evolutionary conservation of a and β tubulin and cytoplasmic β-and γ-actin genes using specific cloned cDNA probes. Cell 20:95, 1980
45. Saleem A, Yuan ZM, Kufe DW, Kharbanda S: Activation of serine/threonine protein kinases and early growth response 1 gene expression by tumor necrosis factor in human myeloid leukemia cells. J Immunol 154:4150, 1995
46. Chauhan D, Kharbanda S, Ogata A, Urashima M, Malik N, Frank D, Kufe D, Anderson KC: Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med 182:1801,1995
47. Nagata S: Fas/Fas ligand: A death factor and its receptor. Adv Immunol 57:129, 1994
48. Nagata S, Goldstein P: The Fas death factor. Science 267:1449, 1995
49. Suda T, Nagata S: Purification and characterization of Fasligand that induces apoptosis. J Exp Med 179:873, 1994
50. Willie AH: Glucocorticoids induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555, 1980
51. Itoh N, Nagata S: A novel protein domain required for apoptosis. Mutational analysis of Fas antigen. J Biol Chem 268:10932, 1993
52. Obeid LM, Linardic CM, Karolak LA, Hannum YA: Programmed cell death induced by ceramide. Science 259:1769, 1993
53. Cifone MG, Maria RD, Rancoaiole P, Rippo MR, Azuma M, Lainier LL, Santoni A, Testi R: Apoptotic signaling through CD95(Fas/APO-1) activates an acidic sphingomyelinase. J Exp Med 177:1547, 1994
54. Enari M, Hug H, Nagata S: Involvement of an ICE/CED-3 protease in Fas-mediated apoptosis. Nature 375:78, 1995
55. Los M, Van de Craen M, Penning LC, Schek H, Westendorf M, Baeurle PA, Droge W, Krammer PH, Fiers W. Schulze-Osthoff K: Requirement of an ICE/CED-3 protease for Fas/APO-1 mediated apoptosis. Nature 375:81, 1995
56. Buttayan R, Olsson CA, Pintar J, Chang C, Bandyk M, Sawczuk IS: Induction of the TRPM-2 gene in cells undergoing programmed cell death. Mol Cell Biol 9:3473, 1989
57. Smeyne RJ, Vendrell M, Hayward M, Baker SJ, Miao GC, Schilling K, Robertson LM, Curran T, Morgan JI: Continuous c-fos precedes programmed cell death in vivo. Nature 363:166, 1993
58. Angel P, Hattori K, Smeal T, Karin M: The jun protoncogene is positively autoregulated by its product, Jun/AP-1. Cell 55:875, 1988
59. Smeal T, Binetruy B, Mercola D, Grover-Bardwick A, Heidecker G, Rapp UR, Karin M: Oncoprotein-mediated signaling cascade stimulates c-Jun activity by phosphorylation of serine 63 and 73. Mol Cell Biol 12:3507, 1992
60. Ong F, Nieuwkoop JAV, Degrootswings GMJS, Hermans J, Harvey MS, Kluin PM, Kluinnelemans JC: BCL-2 protein expression is not related to short survival in multiple myeloma. Leukemia 9:1282, 1995
61. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin-6: A potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008, 1989
62. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H: Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77:2794, 1991
63. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R: Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 85:765, 1995
64. Nakafuku M, Satoh T, Kaziro Y: Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active RAS-GTP complex in rat pheochromocytoma PC12 cells. J Biol Chem 267:19448, 1992
65. Daeipour M, Kumar G, Amaral MC, Nel AE: Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line, AF10. J Immunol 150:4743, 1993
66. Kumar G, Gupta S, Wang S, Nel AE: Involvement of Janus kinases, p52shc, Raf-1 and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line. J Immunol 153: 4436, 1994
67. Billadeau D, Jelinek DF, Shah N, LeBien TW, Ness BV: Introduction of an activated N-ras oncogene alters the growth characteristic of the interleukin 6-dependent myeloma cell line ANBL-6. Cancer Res 55:3640, 1995